secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2024-02-23T23:59:59+00:00
Accession:  0001615219-24-000017
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius extends cash runway into H1 2025; CEO Arthur transitions to part-time consultant
--------------------------------------------------------------------------------

- CEO David Arthur ends full-time employment; becomes part-time consultant effective Feb 20, 2024, at $10,417/month.
- Cash runway expected to extend into first half of 2025 due to cost-saving measures including reduced director pay and operating expenses.
- Ongoing strategic review with Canaccord Genuity to maximize shareholder value; clinical trials in hematologic cancers and Ewing sarcoma continue.
- Clinical data: 50% ORR in hematologic cancers (MDACC trial) and 60% ORR in first-relapse Ewing sarcoma patients with seclidemstat combinations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521924000017/0001615219-24-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521924000017/flks-20240220.htm
  HTML page:      https://secwatch.observer/filing/0001615219-24-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer